Patents by Inventor Stéphane DEGOVE

Stéphane DEGOVE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMH-COMPETITIVE ANTAGONIST ANTIBODY
    Publication number: 20230348607
    Abstract: The present invention relates to a competitive antagonist antibody that specifically binds to AMHR-II, said antibody comprising (a) a heavy chain wherein the variable domain comprises a H-CDR1 having a sequence set forth as SEQ ID NO: 3; a H-CDR2 having a sequence set forth as SEQ ID NO: 4; and a H-CDR3 having a sequence set forth as SEQ ID NO: 5; and (b) a light chain wherein the variable domain comprises at least a CDR selected from the group consisting of a L-CDR1 having a sequence set forth as SEQ ID NO: 8, a L-CDR2 having a sequence set forth as SEQ ID NO: 9; and a L-CDR3 having a sequence set forth as SEQ ID NO: 10. A nucleic acid sequence encoding said antibody, a vector comprising the nucleic acid sequence, a host cell comprising said nucleic acid sequence or vector, an immunoconjugate comprising the said antibody, a pharmaceutical composition comprising the said antibody or immunoconjugate, and the use as a drug of the said antibody, cell or composition is also considered in the present invention.
    Type: Application
    Filed: October 23, 2020
    Publication date: November 2, 2023
    Inventors: Jean-François PROST, Olivier DUBREUIL, Jean-Marc BARRET, Stéphane DEGOVE
  • AMHRII-BINDING COMPOUNDS FOR PREVENTING OR TREATING LUNG CANCERS
    Publication number: 20230227566
    Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a lung cancer, and especially a non-small call lung cancer (NSCLC), and even more especially a NSCLC selected in a group comprising epidermoid NSCLC, adenocarcinoma NSCLC, large cells NSCLC and squamous cell carcinoma NSCLC and neuroendocrine NSCLC.
    Type: Application
    Filed: April 13, 2018
    Publication date: July 20, 2023
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Olivier DUBREUIL, André NICOLAS, Didier MESEURE
  • AMHRII-BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCERS
    Publication number: 20220144959
    Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 12, 2022
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Olivier DUBREUIL, André NICOLAS, Didier MESEURE
  • Anti-human-HER3 antibodies and uses thereof
    Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • CANCER-ASSOCIATED IMMUNOSUPPRESSION INHIBITOR
    Publication number: 20200148777
    Abstract: The present invention relates to a glyco-engineered Fc fragment-bearing compound for its use as an immunosuppression inhibitor in the treatment of a cancer-associated immunosuppression. The invention further relates to a pharmaceutical composition comprising at least this glyco-engineered Fc fragment-bearing compound.
    Type: Application
    Filed: May 29, 2018
    Publication date: May 14, 2020
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Houcine BOUGHERARA, Emmanuel DONNADIEU
  • AMHRII-BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCERS
    Publication number: 20190367625
    Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 5, 2019
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Olivier DUBREUIL, André NICOLAS, Didier MESURE
  • ANTI-HUMAN-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20180155433
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 7, 2018
    Inventors: Thierry CHARDÈS, Olivier DUBREUIL, André PELEGRIN, Christel LARBOURET, Jean-François PROST, Jean-Marc BARRET, Stéphane DEGOVE